Fundz

Lifeward

Marlborough, Massachusetts, United States · Biotechnology, Health Care, Medical · 129 employees

Lifeward is a medical device manufacturer specializing in mobility-related solutions. Their products include the ReWalk Personal Exoskeleton and AlterG Anti-Gravity Systems. Lifeward is dedicated to helping individuals with physical limitations regain mobility. The company is involved in groundbreaking technologies to enhance treatment methodologies.

Funding history

  • Funding Round — $20.0M — Apr 2026
  • Funding Round — $5.0M — Jan 2025
  • Funding Round — $16.3M — Oct 2021
  • Funding Round — $40.0M — Feb 2021
  • Funding Round — $8.0M — Dec 2020

Recent signals

  • May 19, 2026: Lifeward Appoints Dr. Rose as Chief Medical Officer
  • Apr 23, 2026: Lifeward Ltd. Announces Departure of Vice President Jeannine Lynch
  • Apr 23, 2026: SEC 8-K (5.02): On April 20, 2026, Lifeward Ltd. announced the termination of Jeannine Lynch's employment as Vice President of Strategy and Market Access, effective May 3, 2026. The termination will be treated as a 'termination without cause' according to her Employment Agreement dated July 9, 2021. This change in management may impact the company's strategic direction and operational efficiency, as Ms. Lynch was responsible for critical market access strategies. The filing indicates that the decision was made in accordance with the company's internal policies and procedures regarding staff changes.
  • Apr 03, 2026: Acquired Lifeward acquires Oratech Pharmaceuticals for $47M
  • Apr 02, 2026: Raised $20.0M
  • Mar 25, 2026: Acquired Lifeward Ltd. Acquires Oratech Pharma, Inc.
  • Mar 25, 2026: SEC 8-K (2.01): On March 25, 2026, Lifeward Ltd. completed the acquisition of all outstanding equity interests in Oratech Pharma, Inc., a wholly-owned subsidiary of Oramed Pharmaceuticals, Inc. This transaction followed a previously disclosed agreement made on January 12, 2026. The acquisition signifies a strategic expansion for Lifeward Ltd. into the pharmaceutical sector, bolstering its portfolio. Details regarding the financial terms of the transaction are not specified in the report. This acquisition is expected to enhance Lifeward's market position and operational capabilities.
  • Mar 10, 2026: SEC 8-K (8.01): On March 10, 2026, Lifeward Ltd. received written notice from the Nasdaq Listing Qualifications Hearings Department confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which pertains to the Minimum Bid Price Requirement. This compliance was achieved by maintaining a minimum closing bid price of at least $1.00 per share for the last 10 consecutive trading days. The success in meeting this requirement is strategically significant for Lifeward Ltd. as it avoids potential delisting from the Nasdaq Capital Market, ensuring continued access to capital markets and sustaining investor confidence.

See plans & pricing → Track Lifeward’s funding, hiring, and signals — with verified contacts — on Fundz.